Literature DB >> 2512326

Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis.

T R Anderson1, T C Montie, M D Murphy, V P McCarthy.   

Abstract

An enzyme-linked immunosorbent assay specific for flagellum type (a or b) of Pseudomonas aeruginosa was used to detect serum immunoglobulin antibodies in 98 random outpatients and 14 colonized cystic fibrosis patients. Antibodies were detected to both types of flagella in addition to M-2 lipopolysaccharide. Titers to both flagellar antigens (FlAg) were 10 to 100 times higher in cystic fibrosis patients than in random outpatients of a comparable age group. Mean antibody titers against b-type FlAg were 454 for outpatients (ages newborn to 21 years), whereas the mean titer for cystic fibrosis patients (ages 6 to 21 years) was 51,520. Titers against a-type FlAg were generally lower, with mean outpatient titers of 68 and mean cystic fibrosis patient titers of 34,323. Differences were also seen in antibody titer against M-2 lipopolysaccharide, but these differences did not correspond to M-2 FlAg titers. In 98 random outpatients (ages newborn to 86 years), FlAg titers generally increased with age. To demonstrate further specificity of the enzyme-linked immunosorbent assay for flagellum antibody, Western blots were performed with selected high-titer cystic fibrosis patient sera. Sera that had a high titer (greater than 25,600) for b- or a-type FlAg showed a corresponding reactive band. These results demonstrate that flagellum antibodies are produced in humans in response to P. aeruginosa infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512326      PMCID: PMC267127          DOI: 10.1128/jcm.27.12.2789-2793.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

Review 1.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

2.  Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model.

Authors:  T C Montie; D Doyle-Huntzinger; R C Craven; I A Holder
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

3.  Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay.

Authors:  L E Bryan; A Kureishi; H R Rabin
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

4.  Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients.

Authors:  G Döring; V Buhl; N Høiby; P O Schiøtz; K Botzenhart
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-10

5.  Electrophoretic separation and molecular weight characterization of Pseudomonas aeruginosa H-antigen flagellins.

Authors:  J S Allison; M Dawson; D Drake; T C Montie
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

6.  Serial isolates of Pseudomonas aeruginosa from a cystic fibrosis patient have identical pilin sequences.

Authors:  B L Pasloske; A M Joffe; Q Sun; K Volpel; W Paranchych; F Eftekhar; D P Speert
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

7.  Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains.

Authors:  R P Darveau; R E Hancock
Journal:  J Bacteriol       Date:  1983-08       Impact factor: 3.490

8.  Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  G Döring; H J Obernesser; K Botzenhart; B Flehmig; N Høiby; A Hofmann
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

9.  Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition.

Authors:  M A Luzar; M J Thomassen; T C Montie
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

10.  Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis.

Authors:  M Granström; A Ericsson; B Strandvik; B Wretlind; O R Pavlovskis; R Berka; M L Vasil
Journal:  Acta Paediatr Scand       Date:  1984-11
View more
  7 in total

1.  Helicobacter pylori uses motility for initial colonization and to attain robust infection.

Authors:  Karen M Ottemann; Andrew C Lowenthal
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 2.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

3.  Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients.

Authors:  Matthew C Wolfgang; Jeevan Jyot; Andrew L Goodman; Reuben Ramphal; Stephen Lory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

4.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

5.  Role of the Helicobacter hepaticus flagellar sigma factor FliA in gene regulation and murine colonization.

Authors:  Torsten Sterzenbach; Lucie Bartonickova; Wiebke Behrens; Birgit Brenneke; Jessika Schulze; Friederike Kops; Elaine Y Chin; Elena Katzowitsch; David B Schauer; James G Fox; Sebastian Suerbaum; Christine Josenhans
Journal:  J Bacteriol       Date:  2008-08-08       Impact factor: 3.490

6.  Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.

Authors:  W J Landsperger; K D Kelly-Wintenberg; T C Montie; L S Knight; M B Hansen; C C Huntenburg; M J Schneidkraut
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

7.  A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.

Authors:  Gerd Döring; Christoph Meisner; Martin Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-21       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.